Founded in 2009, Leeds-based Arterius is developing a next-generation bioresorbable cardiovascular scaffold (stent) with an emerging market-leading clinical profile. The founding directors have significant experience in the development of medical devices and in the cardiovascular devices field in particular. The development team is supported by a consortium of experts comprising, amongst others, clinical advisory team; computational design group at Southampton University; polymer process engineering at Bradford University and pre-clinical and clinical institutions. Arterius has recently completed the pre-clinical trials and, on the back of these, believes that this collaboration has delivered a next generation drug eluting fully biodegradable stent with a market leading profile.
Arterius was established by Dr Kadem Al-Lamee and Alistair Taylor to exploit opportunities in the $8.1bn coronary stent market. The company has worked in partnership with a consortium of academic contributors consisting of the Computational Design Group at Southampton University, UK; the Polymer Interdisciplinary Research Centre Bradford University, UK; and the Department of Surface Characterisation and Drug Distribution at Nottingham University, UK to design, manufacture and put into pre-clinical evaluation a family of novel vascular scaffold stents, under the trademarked name ArterioSorb™.
Coronary artery disease (also known as coronary heart disease or “CHD”) and ischaemic heart disease are caused by a narrowing (stenosis) of the coronary arteries caused by the deposition of atherosclerotic plaque. These deposits limit the blood flow and supply of oxygen to the heart muscle. The stenosis of arteries may be partial or total. CHD may affect one or more arteries and depending on the diameters of the artery (calibres) and degree of stenosis, may be asymptomatic; lead to chest pain (angina); or, in serious cases, cause acute myocardial infarction (heart attack) or death.
The symptoms and health risks associated with a stenosed artery may be treated medically, by modifying risk factors (for example, smoking, hyperlipidaemia, obesity and hyperglycaemia) and/or by drug treatment (for example, beta-adrenergic blockers, nitrates, calcium-channel blockers, antiplatelet agents and/or statins).
If these medical treatments fail or are inappropriate, two invasive therapies are available: The first, coronary artery bypass grafting (CABG) and involves major cardiac surgery. The second, Percutaneous Coronary Intervention (“PCI”) involves the use of balloon angioplasty to widen an artery from the inside. A balloon catheter is inserted through a femoral artery. When inflated, the balloon increases the calibre of the artery restoring vessel patency and improving blood flow to cardiac muscle. Most PCI procedures involve the use of stents. PCI is a highly effective means of treating acute coronary disease. However medical therapy is often preferable as an initial therapy in patients with stable disease and CABG is more appropriate in patients with highly complex disease, particularly those with diabetes requiring multi-vessel revascularisation.
Arterius has developed a polymer-based bioresorbable scaffold (or “BRS”) ArterioSorb™ that is intended to:
- Match the ease of delivery of Bare Metal Stent (BMS) and Drug Eluting Stent (DES);
- Come in a range of sizes and lengths
- Provide equivalent mechanical performance (radial strength) to the best-in-classDrug Eluting Stent (DES) products
- Generate fewer clinical adverse events than current Drug Eluting Stent (DES)
- Be resorbed within 24 months leaving nothing behind which might complicate future revascularisations
- Overcome the high in-stent late lumen loss (narrowing of the vessel once the stent has dissolved) which has limited the adoption of first generation products
Accomplishing the above will support the positioning of a premium priced BRS product which could claim significant stent market share with higher margins than existing Bare Metal Stent (BMS) and Drug Eluting Stent (DES);